-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Trevi Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2018 to Q4 2024.
- Trevi Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending December 31, 2024 was $17K, a 5.56% decline year-over-year.
- Trevi Therapeutics, Inc. Income Tax Expense (Benefit) for the twelve months ending December 31, 2024 was -$30K, a 6.25% increase year-over-year.
- Trevi Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2024 was -$30K, a 6.25% increase from 2023.
- Trevi Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$32K, a 11.1% increase from 2022.
- Trevi Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was -$36K, a 71.4% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)